Trial Profile
A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms LILAC
- Sponsors Amgen
- 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium.
- 13 Jun 2019 According to an Amgen Media release, Amgen and Allergan plc announced that the U.S. Food and Drug Administration(FDA) has approved KANJINTI™(trastuzumab-anns) for all approved indications of the reference product, Herceptin(trastuzumab) for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
- 04 Jun 2019 Results of an analysis comparing cardiac safety of ABP 980 and trastuzumab reference product (RP) in women with HER2-positive early breast cancer, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.